We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker Used for Febrile Intracranial Hemorrhage Patients

By LabMedica International staff writers
Posted on 27 Jun 2018
Procalcitonin (PCT) is a biomarker that exhibits greater specificity than other proinflammatory markers, such as cytokines, in identifying patients with sepsis and can be used in the diagnosis of bacterial infections.

Intracerebral hemorrhage (ICH) is caused by bleeding within the brain tissue itself, a life-threatening type of stroke. More...
A stroke occurs when the brain is deprived of oxygen and blood supply. ICH is most commonly caused by hypertension, arteriovenous malformations, or head trauma.

Scientists at North Shore University Hospital (Manhasset, NY, USA) and their colleagues enrolled in a prospective observational study 104 patients with intracranial hemorrhage (ICH) and fever above 38.3 ⁰C admitted to Intensive Care Units (ICUs) of a tertiary care hospital. PCT was measured on day one (PCT1) of fever and 48-72h later (PCT2). Patients were determined to have an infection (pneumonia, urinary tract infection or bacteremia) based on cultures, imaging and clinical impression of treating clinicians.

The team used statistical analysis that indicated significant mean differences in PCT1 between patients with no, probable and definite infection. Patients with probable infection had the highest mean PCT1 and those with definite infection had higher PCT2. Additional analyses of univariable mean differences showed a mean PCT1 that was significantly higher in the probable-infection group compared with the no-infection group and mean PCT that was significantly higher at both time points in the definite-infection group compared with the no-infection group; however, there were no significant differences between the probable and definite-infection group.

The authors concluded that PCT levels were higher in patients with ICH and infections, and may be a useful marker to differentiate between infectious and noninfectious etiologies of fevers in these patients. Further studies including randomized control trials will help in establishing the utility of this marker in optimal management of febrile patients with ICH. The study was published on May 29, 2018, in the journal World Neurosurgery.

Related Links:
North Shore University Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.